Lianhuan Pharmaceutical released its 2026 interim report. Total operating revenue reached 1.571 billion yuan, an increase of 285 million yuan compared with the same period last year, marking five consecutive years of growth and a year-on-year rise of 22.21%. Net profit attributable to the parent company was 10.52 million yuan, an increase of 50.55 million yuan from the same period last year, turning losses into gains. Net cash flow from operating activities was negative 84.62 million yuan, an improvement of 73.19 million yuan compared with the same period last year. The company's latest asset-liability ratio was 60.56%, gross margin was 28.67%, return on equity was 0.83%, and diluted earnings per share was 0.04 yuan.
Jiangsu Lianhuan Pharmaceutical Co LtdNet profit turned from loss to gain of 10.52 million yuan, with revenue up 22.21%.
